CSL share price pressure deepened after the company cut FY26 guidance and said it plans about $5 billion in additional asset impairments. The 90-day interim CEO review pushed the stock back into focus for investors who have already seen CSL shares fall 49% over the past 12 months.
Gordon Naylor Cuts FY26
Gordon Naylor said, "As a result, we have now revised down our 2026 financial year guidance." He also said, "Our growth initiatives are working, but the financial benefits will take longer than previously anticipated to materialise."
That is the core shift for CSL holders: the company is still pointing to growth initiatives, but the payoff is now expected later than it had been. For a market that has already marked the stock down far more than the broader index, the new guidance reset gives traders a fresh number to price against rather than a vague management promise.
$5 Billion Impairment Charge
$5 billion in additional asset impairments is the other headline figure, and it sits beside the guidance cut as the most immediate earnings hit. CSL did not present the charge as tied to a single division in the facts provided, but the size of the write-down is large enough to weigh on reported profit expectations even if operating trends later improve.
CSL said its core business in plasma collection and influenza vaccines remains strong, and that ongoing demand growth continues in key markets. It also said US Immunoglobulin and Albumin product segments are seeing stable or rising demand, which leaves the company pointing to resilient end markets even as short-term revenue has been hit by price pressure and changes in market dynamics.
CSL Behring And Seqirus
CSL said its transformation and efficiency program is targeting $500 million to $550 million in annual savings by FY28. It also said CSL Seqirus is tracking moderately ahead of earlier forecasts for the year, while CSL expects revenue growth in its CSL Behring division in the second half of FY26 and said Seqirus is anticipated to outperform previous forecasts.
The split message is straightforward: near-term revenue has been pressured, but two operating franchises are still expected to improve relative to earlier forecasts. If those savings and second-half growth plans land, the company has a path back toward profit improvement; if they do not, the impairment charge will sit alongside a slower-than-hoped earnings recovery.
August 2026 Update
CSL said a global search for a permanent CEO is progressing, and commercial leadership will transition to Diego Sacristan from 1 July 2026. Naylor said, "I am confident that the company can be returned to profitable growth and my work is to position the business and the next CEO for success." CSL said it will provide a further update with its full-year results in August 2026.
